Modulation of alternative splicing by anticancer drugs

E-ISSN： 1757-7012|6|4|369-379

ISSN： 1757-7004

Source： WILEY INTERDISCIPLINARY REVIEWS: RNA (ELECTRONIC), Vol.6, Iss.4, 2015-07, pp. : 369-379

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Pre‐mRNA alternative splicing is a highly regulated process that generates multiple mRNAs coding different protein isoforms. These protein isoforms may have similar, different, or even opposing functions. Expression of genes involved in cell growth and apoptosis are often altered in cancer cells. Studying the alternative splicing patterns of these important genes can have a significant role in the treatment of cancer. Resistance to chemotherapy is often caused due to overexpression of anti‐apoptotic isoforms or suppression of pro‐apoptotic isoforms. Anticancer drugs are capable of modulating the expression of different transcript isoforms of genes. Some anticancer drugs induce pro‐apoptotic transcript isoforms leading to apoptosis or at least sensitizing cells to chemotherapy. However, in other cases, they shift the splicing toward isoforms having anti‐apoptotic functions thus conferring resistance to chemotherapy. This mini‐review summarizes the current knowledge about alternative splicing of some important genes involved in cancers. Furthermore, splicing patterns as well as generation of functionally distinct protein isoforms have also been mentioned. Role of various anticancer drugs in modulating alternative splicing of these genes has been reported along with a brief insight into their mechanism of action. Modulation of alternative splicing toward production of pro‐apoptotic isoforms of various genes by anticancer drugs offers great therapeutic potential in the treatment of cancer. WIREs RNA 2015, 6:369–379. doi: 10.1002/wrna.1283For further resources related to this article, please visit the WIREs website.Conflict of interest: The authors declare that there is no conflict of interest in this article.